Skip to Content

Menveo Side Effects

Generic Name: meningococcal conjugate vaccine

Note: This document contains side effect information about meningococcal conjugate vaccine. Some of the dosage forms listed on this page may not apply to the brand name Menveo.

For the Consumer

Applies to meningococcal conjugate vaccine: intramuscular powder for suspension, intramuscular suspension

Other dosage forms:

Along with its needed effects, meningococcal conjugate vaccine (the active ingredient contained in Menveo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking meningococcal conjugate vaccine:

Rare

  • Cough
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • hives
  • itching
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • shortness of breath
  • skin rash
  • tightness in the chest
  • unusual tiredness or weakness
  • wheezing

Incidence Not Known

  • Inability to move the arms and legs
  • fainting
  • sudden and progressing muscle weakness
  • sudden and severe back pain
  • sudden numbness and weakness in the arms and legs
  • weakness of the muscles in your face

Some side effects of meningococcal conjugate vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Chills
  • diarrhea
  • difficulty with moving
  • fever
  • general feeling of discomfort or illness
  • hard lump at the injection site
  • headache
  • irritability
  • loss of appetite
  • muscle pain or stiffness
  • pain in the joints
  • pain, redness, or swelling at the injection site
  • sleepiness
  • weight loss

Less Common

For Healthcare Professionals

Applies to meningococcal conjugate vaccine: intramuscular powder for injection, intramuscular solution

General

The most common adverse events were injection site pain, irritability, diarrhea, headache, and fatigue.[Ref]

Local

Very common (10% or more): Injection site pain (48.1%), injection site redness (16%), injection site induration (11%)

Common (1% to 10%): Injection site swelling, injection site hematoma

Uncommon (0.1% to 1%): Injection site pruritus

Postmarketing reports: Injection site reaction, injection site cellulitis, extensive swelling of the injected limb (frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb)[Ref]

Nervous system

Very common (10% or more): Headache (41.8%), drowsiness (11.2%)

Uncommon (0.1% to 1%): Dizziness, hypoesthesia

Postmarketing reports: Vasovagal syncope, paresthesia, Guillain-Barre syndrome, vertigo, tonic convulsion, febrile convulsion, vertigo, vestibular disorder, syncope, facial paresis, balance disorder[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (14%), nausea

Common (1% to 10%): Vomiting, gastrointestinal symptoms[Ref]

Other

Very common (10% or more): Fatigue (32.3%), malaise (22.3%), fever

Common (1% to 10%): Chills, crying

Postmarketing reports: Asthenia, impaired hearing, ear pain, fall, head injury, body temperature increased[Ref]

Dermatologic

Common (1% to 10%): Rash

Uncommon (0.1% to 1%): Pruritus

Postmarketing reports: Bullous conditions[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (16%), myalgia

Uncommon (0.1% to 1%): Pain in extremity

Postmarketing reports: Bone pain[Ref]

Psychiatric

Very common (10% or more): Irritability (12.2%)

Common (1% to 10%): Insomnia[Ref]

Metabolic

Very common (10% or more): Appetite lost

Common (1% to 10%): Anorexia, eating disorder[Ref]

Respiratory

Uncommon (0.1% to 1%): Nasopharyngitis

Postmarketing reports: Oropharyngeal pain[Ref]

Hypersensitivity

Postmarketing reports: Hypersensitivity (such as rash, urticaria, pruritus, dyspnea, angioedema) including anaphylaxis[Ref]

Hepatic

Postmarketing reports: Alanine aminotransferase increased[Ref]

Ocular

Postmarketing reports: Eyelid ptosis[Ref]

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur, Swiftwater, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide